The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominately entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira), however, recent entries that offer alternative treatment options for TNF-α refractory patients (i.e., Takeda’s Entyvio and Janssen’s Stelara), as well as the arrival of biosimilar infliximab (Pfizer’s Inflectra), continue to evolve the UC/CD treatment landscapes.
The potential arrival of several more agents offering novel MOAs and/or formulations (e.g., Pfizer’s tofacitinib, Gilead/Galapagos’ filgotinib, Roche/Genentech’s etrolizumab), as well as increasing physician experience prescribing biosimilars will fuel competition and pricing pressure these markets. Emerging therapies looking to gain favorable uptake in UC and/or CD will face a growing number of challenges to impress physicians and payers alike, and may struggle to gain robust uptake and/or favorable formulary placement.
This report provides answers to the following questions:
Access & Reimbursement Solution
This report provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning. Learn more about how you can quickly identify, analyze, and act on emerging challenges with timely and accurate insights DRG’s Insights Platform.